Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Medical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Crit Rev Oncol Hematol. 2019 Nov;143:20-26. doi: 10.1016/j.critrevonc.2019.07.010. Epub 2019 Aug 12.
Approximately 30-50% of advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer patients will develop brain metastases (BMs) during the disease course. Brain metastases may become a main limitation of life expectancy and a half of them will die from brain progression. Even in patients with early HER2-positive breast cancer managed with curative therapy, the risk of brain metastases is also increased. Central nervous system (CNS) may usually present as the first site of recurrence in HER2-positive breast cancer. Local treatments including radiotherapy and surgery are essential while new chemotherapy and biological agents appear to contribute a significant role in the future treatment field of CNS metastases. This article will review recent progresses in HER2-positive breast cancer with BM, with a focus on the efficacy of the HER2 targeted agents-trastuzumab emtansine (T-DM1).
约 30-50%的晚期人表皮生长因子受体 2（HER2）阳性乳腺癌患者在疾病过程中会发展为脑转移（BM）。脑转移可能成为预期寿命的主要限制因素，其中一半患者将死于脑转移进展。即使在接受根治性治疗的早期 HER2 阳性乳腺癌患者中，脑转移的风险也会增加。中枢神经系统（CNS）通常是 HER2 阳性乳腺癌复发的第一部位。局部治疗（包括放疗和手术）至关重要，而新的化疗和生物制剂似乎在 CNS 转移的未来治疗领域发挥重要作用。本文将综述 HER2 阳性乳腺癌伴 BM 的最新进展，重点介绍 HER2 靶向药物曲妥珠单抗-美坦新偶联物（T-DM1）的疗效。
